JAGUAR HEALTH, INC. Restricted Cash
JAGUAR HEALTH, INC. (JAGX) had Restricted Cash of $2.80 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-08-19
- 2026-06-30: Restricted Cash $2.80M.
- 2026-03-31: Restricted Cash $2.79M.
- 2025-12-31: Restricted Cash $6.86M.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $2.79M 10-Q · filed 2026-05-20 |
| 2025-12-31 | $6.86M 10-K · filed 2026-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |